The CEA Registry Blog

Feb 6

by CEA Registry Team 2/6/2017 4:57 PM  RssIcon

 This week we highlighted findings from recently published cost-effectiveness studies:

  • New insights into methodological derivation of thresholds used in global health:New paper reviews the underlying  concepts of CEA thresholds, the derivation of the one and three times GDP per capital multipliers, and suggestions for improvement in global health research (46)
  • Use of specialized oral nutritional supplements suggests considerable cost-effectiveness: Providing specialized oral nutritional supplements to prevent and combat malnutrition in older hospitalized patients was found to extend the life of patients with favorable cost-effectiveness (58)
See below for a full list of all cost-utility studies and selected reviews and editorials published January 30 – February 3, 2017.  To discover more CEA articles or to dive in-depth on some of these topics, please visit the Tufts CEA Registry.  Follow us on Twitter (@TuftsCEVR) and Facebook.
1: Aichmair A, et al. Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS). Eur Spine J. 2017 Feb;26(2):501-509. PMID: 28040872.
2: Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky MA. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. JACC Heart Fail. 2017 Feb;5(2):110-119. PMID: 28017351.
3: Barbosa C, Cowell A, Dowd W, Landwehr J, Aldridge A, Bray J. The cost-effectiveness of brief intervention versus brief treatment of Screening, Brief Intervention and Referral to Treatment (SBIRT) in the United States. Addiction. 2017 Feb;112 Suppl 2:73-81. PMID:28074567.
4: Bardach AE, et al. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health. 2017 Feb 2;17(1):152. PMID: 28148228.
5: Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, Yang Y, Li Q. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol. 2017 Feb;143(2):361-368. PMID: 27798730.
6: Choi SE, Seligman H, Basu S. Cost Effectiveness of Subsidizing Fruit and Vegetable Purchases Through the Supplemental Nutrition Assistance Program. Am J Prev Med. 2017 Jan 30. PMID: 28153648.
7: Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom. Pharmacoeconomics. 2017 Feb;35(2):237-248. PMID: 27787744.
8: Connell NT, Abel GA, Connors JM. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thromb Res. 2017 Feb;150:53-58. PMID: 28039844.
9: Costa D, Peixoto Lima R. Cost-effectiveness of ambulatory blood pressure monitoring in the management of hypertension. Rev Port Cardiol. 2017 Jan 31. English, Portuguese. PMID: 28159431.
10: Coyle D. Increasing the methodological quality and relevance of cost effectiveness analysis. Thromb Res. 2017 Feb;150:121-122. PMID: 28007401.
11: Cradock AL, et al. Using cost-effectiveness analysis to prioritize policy and programmatic approaches to physical activity promotion and obesity prevention in childhood. Prev Med. 2017 Feb;95S:S17-S27. PMID: 27773710.
12: Critchlow S, Hirst M, Akehurst R, Phillips C, Philips Z, Sullivan W, Dunlop WC. A systematic review of cost-effectiveness modeling of pharmaceutical therapies in neuropathic pain: variation in practice, key challenges, and recommendations for the future. J Med Econ. 2017 Feb;20(2):129-139. PMID: 27563752.
13: Cubo E, et al. Prospective study on cost-effectiveness of home-based motor assessment in Parkinson's disease. J Telemed Telecare. 2017 Feb;23(2):328-338. PMID: 27000142.
14: de Vos AS, Janssen MP, Zaaijer HL, Hogema BM. Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands. Transfusion. 2017 Jan 31. PMID: 28144956.
15: Elbasha EH, Robertson MN, Nwankwo C. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States. Aliment Pharmacol Ther. 2017 Feb;45(3):455-467. PMID: 27910116.
16: Elmallah RK, Chughtai M, Khlopas A, Bhowmik-Stoker M, Bozic KJ, Kurtz SM, Mont MA. Determining Cost-Effectiveness of Total Hip and Knee Arthroplasty Using  the Short Form-6D Utility Measure. J Arthroplasty. 2017 Feb;32(2):351-354. PMID: 27665243.
17: Floodeen H, Hallböök O, Hagberg LA, Matthiessen P. Costs and resource use following defunctioning stoma in low anterior resection for cancer - A long-term analysis of a randomized multicenter trial. Eur J Surg Oncol. 2017 Feb;43(2):330-336. PMID: 28069399.
18: Fust K, et al. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):39-52. PMID: 28064553.
19: Gilden DM, et al. Treatment patterns and cost-effectiveness of first line treatment of
advanced non-squamous non-small cell lung cancer in Medicare patients. J Med Econ. 2017 Feb;20(2):151-161. PMID: 27574722.
20: Grabner M, Winegar DA, Punekar RS, Quimbo RA, Cziraky MJ, Cromwell WC. Cost
Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level. Am J Cardiol. 2017 Feb 1;119(3):404-409. PMID: 27887691.
21: Groessl EJ, Sklar M, Laurent DD, Lorig K, Ganiats TG, Ho SB. Cost-Effectiveness of the Hepatitis C Self-Management Program. Health Educ Behav. 2017 Feb;44(1):113-122. PubMed PMID: 27206463.
22: Hagberg L, Hermansson L, Fredriksson C, Pettersson I. Cost-effectiveness of powered mobility devices for elderly people with disability. Disabil Rehabil Assist Technol. 2017 Feb;12(2):115-120. PMID: 25634493.
23: Hernandez I, Smith KJ, Zhang Y. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thromb Res. 2017 Feb;150:123-130. PMID: 27771008.
24: Hojjat H, et al. Cost-effectiveness of routine computed tomography in the evaluation
of idiopathic unilateral vocal fold paralysis. Laryngoscope. 2017 Feb;127(2):440-444. PMID: 27601300.
25: Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, Velcheti V. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. J Med Econ. 2017 Feb;20(2):140-150. PMID: 27571538.
26: Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol. 2017 Feb;52(2):238-241. PMID: 27806639.
27: Kearns B, Chilcott J, Whyte S, Preston L, Sadler S. Erratum to: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Med. 2017 Feb 3;15(1):31. PMID: 28158977.
28: Kievit W, Maurits JS, Arts EE, van Riel PL, Fransen J, Popa CD. Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):175-182. PMID: 27159060.
29: Landfeldt E, Alfredsson L, Straub V, Lochmüller H, Bushby K, Lindgren P. Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 Feb;35(2):249-258. PMID: 27798808.
30: Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):85-98. PMID: 27366939.
31: Lawson R, Ryan J, King F, Goh JW, Tichy E, Marsh K. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK. Pharmacoeconomics. 2017 Feb;35(2):225-235. PMID: 27663572.
32: Le P, Rothberg MB. Determining the Optimal Vaccination Schedule for Herpes Zoster: a Cost-Effectiveness Analysis. J Gen Intern Med. 2017 Feb;32(2):159-167. PMID: 27743284.
33: Leal J, et al. Cost-Effectiveness of Orthogeriatric and Fracture Liaison Service Models of Care for Hip Fracture Patients: A Population-Based Study. J Bone Miner Res. 2017 Feb;32(2):203-211.PMID: 27632945.
34: Leidner AJ, Chesson HW, Spradling PR, Holmberg SD. Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Appl Health Econ Health Policy. 2017 Feb;15(1):65-74. PMID: 27480538.
35: McLean TR. Interval Appendectomy: Cost-Effectiveness. J Am Coll Surg. 2017 Feb;224(2):219. PMID: 28129836.
36: Moradi-Lakeh M, Yaghoubi M, Hajebi A, Malakouti SK, Vasfi MG. Cost-effectiveness of aftercare services for people with severe mental disorders: an analysis parallel to a randomised controlled clinical trial in Iran. Health Soc Care Community. 2017 Feb 1. PMID: 28147433.
37: Mori T, Crandall CJ, Ganz DA. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. Osteoporos Int. 2017 Feb;28(2):585-595. PMID: 27726000.
38: Muralidhar V, Nguyen PL. Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urol Oncol. 2017Feb;35(2):76-85. PMID:27473636.
39: Neidell M, Lamster IB, Shearer B. Cost-effectiveness of diabetes screening initiated through a dental visit. Community Dent Oral Epidemiol. 2017 Feb 1. PMID: 28145564.
40: Osterberg EC, Murphy G, Harris CR, Breyer BN. Cost-effective Strategies for the Management and Treatment of Urethral Stricture Disease. Urol Clin North Am. 2017 Feb;44(1):11-17. PMID:27908365.
41: Panman C, Wiegersma M, Kollen BJ, Berger MY, Lisman-Van Leeuwen Y, Vermeulen
KM, Dekker JH. Two-year effects and cost-effectiveness of pelvic floor muscle training in mild pelvic organ prolapse: a randomised controlled trial in primary care. BJOG. 2017 Feb;124(3):511-520. PMID: 26996291.
42: Pedersen K, Sørbye SW, Kristiansen IS, Burger EA. Using novel biomarkers to triage young adult women with minor cervical lesions: a cost-effectiveness analysis. BJOG. 2017 Feb;124(3):474-484. PMID: 27264207.
43: Permsuwan U, Dilokthornsakul P, Thavorn K, Saokaew S, Chaiyakunapruk N. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand. J Med Econ. 2017 Feb;20(2):171-181. PMID: 27645706.
44: Qu XM, Louie AV, Ashman J, Wasif N. Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):339-346. PMID: 28068242.
45: Ristau BT, Geynisman DM. Patient-reported and Cost-effectiveness Outcomes Are
Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma. Eur Urol. 2017 Feb;71(2):210-212. PMID: 27638095.
46: Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017 Feb;32(1):141-145. PMID: 27452949.
47: Shafie AA, Ng CH, Tan YP, Chaiyakunapruk N. Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. Pharmacoeconomics. 2017 Feb;35(2):141-162. PMID: 27752998.
48: Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. Curr Med Res Opin. 2017 Feb;33(2):359-369. PMID: 27817216.
49: Shireman TI, et al. Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for
Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). Stroke. 2017 Feb;48(2):379-387. PMID:28028150.
50: Smith SR, et al. Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2017 Feb;69(2):234-242. PMID: 27111538.
51: Swart E, Laratta J, Slobogean G, Mehta S. Operative Treatment of Rib Fractures in Flail Chest Injuries: A Meta-analysis and Cost-Effectiveness Analysis. J Orthop Trauma. 2017 Feb;31(2):64-70. PMID: 27984449.
52: Vidal J, Slof J, Serrano D, Marqués T, Kumru H, Benito-Penalva J. Cost-effectiveness of Intrathecal Baclofen Therapy in severe refractory non-focal disabling spasticity: a Spanish hospital perspective. Expert Rev Pharmacoecon Outcomes Res. 2017 Feb;17(1):67-76. PMID: 27142176.
53: Vodicka EL, et al. Costs of integrating cervical cancer screening at an HIV clinic in Kenya. Int J Gynaecol Obstet. 2017 Feb;136(2):220-228.
54: Wang J, Chmielowski B, Pellissier J, Xu R, Stevinson K, Liu FX. Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States. J Manag Care Spec Pharm. 2017 Feb;23(2):184-194. PMID: 28125365.
55: Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD,Campbell JD. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017 Feb;118(2):220-225. PMID: 27923549.
56: Yanagi Y, Fukuda A, Barzey V, Adachi K. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan. J Med Econ. 2017 Feb;20(2):204-212. PMID: 27701921.
57: Yoshimura M, Moriwaki K, Noto S, Takiguchi T. A model-based cost-effectiveness analysis of osteoporosis screening and treatment strategy for postmenopausal Japanese women. Osteoporos Int. 2017 Feb;28(2):643-652. PMID: 27743068.
58: Zhong Y, Cohen JT, Goates S, Luo M, Nelson J, Neumann PJ. The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. Appl Health Econ Health Policy. 2017 Feb;15(1):75-83. PMID: 27492419.


Your name:
Security Code
Enter the code shown above in the box below
Add Comment   Cancel 

Please view the blog archive for earlier entries

Search This Blog


Blog Archive

<April 2018>
February, 2018 (1)
December, 2017 (1)
November, 2017 (1)
October, 2017 (2)
August, 2017 (1)
June, 2017 (1)
May, 2017 (4)
April, 2017 (4)
March, 2017 (3)
February, 2017 (6)
January, 2017 (6)
December, 2016 (4)
November, 2016 (4)
October, 2016 (3)
September, 2016 (2)
August, 2016 (1)
June, 2016 (1)
May, 2016 (1)
February, 2016 (2)
November, 2015 (1)
September, 2015 (2)
August, 2015 (1)
July, 2015 (2)
June, 2015 (5)
May, 2015 (6)
April, 2015 (4)
March, 2015 (6)
February, 2015 (6)
January, 2015 (5)
December, 2014 (5)
November, 2014 (2)
October, 2014 (5)
September, 2014 (7)
August, 2014 (5)
July, 2014 (3)
June, 2014 (2)
May, 2014 (1)
April, 2014 (3)
March, 2014 (3)
February, 2014 (3)
November, 2013 (1)
October, 2013 (4)
September, 2013 (4)
August, 2013 (9)
July, 2013 (7)
June, 2013 (6)
May, 2013 (4)
April, 2013 (4)
March, 2013 (6)
February, 2013 (7)
January, 2013 (5)
December, 2012 (6)
November, 2012 (8)
October, 2012 (11)
September, 2012 (9)
August, 2012 (10)
July, 2012 (11)
June, 2012 (10)
May, 2012 (10)
April, 2012 (9)
March, 2012 (9)
February, 2012 (7)
January, 2012 (4)
December, 2011 (3)
November, 2011 (5)
October, 2011 (8)
September, 2011 (6)
August, 2011 (4)
July, 2011 (10)
June, 2011 (8)
May, 2011 (10)
April, 2011 (9)
March, 2011 (9)
February, 2011 (8)
January, 2011 (6)
December, 2010 (7)
November, 2010 (10)
October, 2010 (7)
September, 2010 (5)
August, 2010 (8)
July, 2010 (13)
June, 2010 (8)
May, 2010 (9)
April, 2010 (7)
March, 2010 (5)
February, 2010 (9)
January, 2010 (2)
August, 2009 (1)
May, 2009 (1)
April, 2009 (1)
March, 2009 (1)
November, 2008 (1)